Hims & Hers’ stock tumbles on Amazon’s latest disruptive foray into healthcare
Hims & Hers Health Inc. shares tumbled 22% Thursday, on concerns that Amazon.com Inc.’s latest push into healthcare will disrupt Hims & Hers’ business. Amazon One Medical launched a new service Thursday that offers upfront pricing for telehealth visits for a range of issues and ailments — including men’s hair loss,
What's Going On With Hims & Hers Health Stock On Wednesday?
Hims & Hers Health launched a GLP-1 Supply Tracker to spotlight challenges in accessing obesity medications, addressing rising demand and pharmacy shortages.
Amazon's push into telehealth knocks shares of Hims & Hers
Shares of Hims & Hers have more than doubled this year after the company began offering compounded GLP-1 weight-loss injections, such as Novo Nordisk's Wegovy. Amazon's move makes Hims & Hers' strategy to personalize treatment via compounding ever-more ...
Amazon Gets Into the Boner Pill Business, Hims Stock Goes Limp
The pricing will show up at checkout when users are logged into Amazon with a Prime membership. Amazon acquired primary care provider One Medical for $3.9 billion in 2022, and fills prescriptions through Amazon Pharmacy.
Hims & Hers stock falls as Amazon launches Telehealth offering
Shares of Hims & Hers Health, Inc. (HIMS) dropped over 15% Thursday following Amazon’s announcement of new telehealth treatment options aimed at providing low-cost care for a range of health and beauty concerns,
Hims & Hers drops 17% as Amazon rolls out expanded telehealth service
Shares of telehealth services provider Hims & Hers (NYSE:HIMS) fell 17% in morning trading Thursday after Amazon (NASDAQ:AMZN) announced it was launching an expanded pay-per-visit telehealth service,
Hims & Hers launches GLP-1 tracker in response to FDA's shortage decision
Hims & Hers (HIMS) is launching a new GLP-1 tracker in its efforts to fight back against the FDA’s decision to end compounded ...
Becker's Hospital Review8h
Hims & Hers launches GLP-1 tracker amid shortages
Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.
Hims & Hers launching GLP-1 tracker, Yahoo Finance reports
In response to the FDA’s shortage decision, Hims & Hers is launching a new GLP-1 tracker, allowing patients to self-identify, provide ...
After Another Blowout Quarter of Surging Revenue, Is Hims & Hers Stock a Once-in-a-Decade Buy?
Hims & Hers once again delivered a blowout quarter with surging revenue. Revenue soared 77% year over year to $401.6 million, ...
Seeking Alpha9d
Hims & Hers: A Lot More Than Just GLP-1, And It's Proving Its Ability To Grow
HIMS boasts high gross margins (~80%) with no R&D risk, capitalizing on the shift away from traditional pharmacies to ...
Drug Store News1d
Hims & Hers Health plans to launch generic of Novo Nordisk's Victoza
Hims & Hers Health, a telehealth company, is planning to offer a generic version of Novo Nordisk's diabetes drug, liraglutide ...
Modern Healthcare2d
Hims & Hers, Talkspace among Q3 winners in digital health
Digital health companies faced high advertising costs and focused on returns on investments in the third quarter.
Yahoo Finance1d
Hims & Hers Stock Gains 31.1% Since Q3 Earnings: What's Next?
The company reported its third-quarter 2024 earnings on Nov. 4. Another major development from HIMS in recent months includes the announcement of access to the most common compounded GLP-1 ...